Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Sleep Initiation and Maintenance Disorders: HELP
Articles from Miscellaneous institutions in Irvine
Based on 2 articles published since 2008

These are the 2 published articles about Sleep Initiation and Maintenance Disorders that originated from Miscellaneous institutions in Irvine during 2008-2019.
+ Citations + Abstracts
1 Article Neurofeedback or neuroplacebo? 2017

Thibault, Robert T / Lifshitz, Michael / Raz, Amir. ·Institute for Interdisciplinary Behavioral and Brain Sciences, Chapman University, Irvine, CA, 92618, USA. · Departments of Psychiatry, Neurology and Neurosurgery, and Psychology, McGill University, Montreal, H3A 2B4, Canada. · The Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, H3T 1E4, Canada. ·Brain · Pubmed #28375458.

ABSTRACT: -- No abstract --

2 Article The effect of herbal extract (EstroG-100) on pre-, peri- and post-menopausal women: a randomized double-blind, placebo-controlled study. 2012

Chang, Albert / Kwak, Bo-Yeon / Yi, Kwontaek / Kim, Jae Soo. ·Shady Canyon Medical Group, 16300 Sand Canyon, Suite 909, Irvine, CA 92618, USA. shadycanyon@yahoo.com ·Phytother Res · Pubmed #21887807.

ABSTRACT: This clinical research study was designed to evaluate the efficacy of a new herbal product, EstroG-100, containing a mixture of standardized extracts of Cynanchum wilfordii, Phlomis umbrosa and Angelica gigas, on menopausal symptoms. This randomized double-blind, placebo-controlled trial was performed for 12 weeks with 64 pre-, peri- and postmenopausal White Hispanic, White non-Hispanic and African American women who were randomly allocated to either the EstroG-100 group (n = 31) or the placebo group (n =  33). Primary end-points were the mean change in scores of the Kupperman menopause index (KMI) that evaluates 11 symptoms, and the mean change in scores of vaginal dryness. The mean KMI score was significantly reduced in the EstroG-100 group from 29.5 ± 7.4 at baseline to 11.3 ± 5.8 (p < 0.01) compared with change of the placebo group (29.2 ± 6.6 at baseline vs 23.7 ± 7.7 at week 12). The constituting symptoms of vasomotor, paresthesia, insomnia, nervousness, melancholia, vertigo, fatigue and rheumatic pain were significantly improved in the EstroG-100 group in comparison with the placebo group (p < 0.05). Statistically significant improvement in vaginal dryness in the EstroG-100 group was also observed compared with that of the placebo group (p < 0.05). In conclusion, EstroG-100 significantly improved the menopausal symptoms of pre-, peri- and post-menopausal women without weight gain or any serious side effects.